A State-Run Enterprise: A Bane or a Boon?

by Sungjune KIM
Published 2015-09-01

The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?

by Lin Zhang, Lin Zhang, Lin Zhang, Sungjune Kim, Xiubao Ren, Xiubao Ren, Xiubao Ren
Published 2020-09-01

Targeting the Mechanisms of Resistance to Chemotherapy and Radiotherapy with the Cancer Stem Cell Hypothesis

by Ryan Morrison, Stephen M. Schleicher, Yunguang Sun, Kenneth J. Niermann, Sungjune Kim, Daniel E. Spratt, Christine H. Chung, Bo Lu
Published 2011-01-01

280 Both tumor intrinsic and extrinsic factors contribute to TIL resistance in lung cancer patients

by David Noyes, Chao Wang, Scott Antonia, Jose Conejo-Garcia, Bin Fang, John Koomen, Jamie Teer, Jiqiang Yao, Carmen Anadon, Ana Landin, Xiaoqing Yu, Dongliang Du, Zachary Thompson, Sungjune Kim, Dung-Tsa Chen, Eric Haura, Ben Creelan
Published 2020-11-01

Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study

by Kamran A. Ahmed, MD, Youngchul Kim, PhD, John A. Arrington, MD, Sungjune Kim, MD, PhD, Michelle DeJesus, BS, Aixa E. Soyano, MD, Avan J. Armaghani, MD, Ricardo L.B. Costa, MD, Hung T. Khong, MD, Loretta S. Loftus, MD, Marilin Rosa, MD, Jimmy J. Caudell, MD, PhD, Roberto Diaz, MD, PhD, Timothy J. Robinson, MD, PhD, Arnold B. Etame, MD, PhD, Nam D. Tran, MD, PhD, Solmaz Sahebjam, MD, Hatem H. Soliman, MD, Brian J. Czerniecki, MD, PhD, Peter A. Forsyth, MD, H. Michael Yu, MD, Hyo S. Han, MD
Published 2021-11-01